Form 4: Arcturus Therapeutics Director Acquires Stock Options

Arcturus Therapeutics Holdings Inc. reports that Director Magda Marquet acquired 15,000 stock options.

Summary

• Director Magda Marquet acquired 15,000 stock options for Arcturus Therapeutics Holdings Inc. common stock.
• The transaction occurred on June 5, 2026, with an exercise price of $7.30 per share.
• These options are part of the 2026 annual grant to the reporting person for her role as a member of the Board of Directors.
• The shares underlying the options vest monthly over a one-year period from the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director compensation practice rather than a significant new development or financial result.

Positives

• Director's acquisition of stock options signals confidence in the company's future prospects.
• The grant of options aligns the director's interests with those of shareholders.
• The options have a vesting schedule, encouraging continued service and performance.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook from management regarding the company's future performance, as these options are typically granted with the expectation that the stock price will increase.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, used as a tool for executive compensation and to incentivize long-term value creation.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially leading to decisions that enhance shareholder value.

Next Steps

• Monthly vesting of the underlying shares over a one-year period.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Form 4, Stock Options, Director Grant, Beneficial Ownership, SEC Filing